| P50 | author | Nadia Rucci | Q57097988 |
| | Adriano Angelucci | Q37376552 |
| P2093 | author name string | Nadia Rucci | |
| | Adriano Angelucci | |
| P2860 | cites work | Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 |
| | Abiraterone in metastatic prostate cancer without previous chemotherapy | Q24612084 |
| | Wnt/beta-catenin signaling in development and disease | Q27860784 |
| | LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development | Q28206790 |
| | Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma | Q28206821 |
| | High bone density due to a mutation in LDL-receptor-related protein 5 | Q28217891 |
| | Bone sialoprotein stimulates focal adhesion-related signaling pathways: role in migration and survival of breast and prostate cancer cells | Q28247265 |
| | Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study | Q28275476 |
| | Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems | Q28294477 |
| | Secreted antagonists of the Wnt signalling pathway | Q29615521 |
| | Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer | Q29616218 |
| | Alpha emitter radium-223 and survival in metastatic prostate cancer | Q29617472 |
| | Increased survival with enzalutamide in prostate cancer after chemotherapy | Q29617511 |
| | Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial | Q29620155 |
| | Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment | Q30304016 |
| | Establishment of human prostate carcinoma skeletal metastasis models | Q30305852 |
| | Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells | Q30308220 |
| | Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis | Q30432069 |
| | Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions | Q30435146 |
| | Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone | Q40713735 |
| | Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. | Q40958936 |
| | ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. | Q40966152 |
| | Bone sialoprotein supports breast cancer cell adhesion proliferation and migration through differential usage of the alpha(v)beta3 and alpha(v)beta5 integrins | Q41017355 |
| | Osteopetrosis in mice lacking haematopoietic transcription factor PU.1. | Q41121255 |
| | Metastatic prostate cancer in a transgenic mouse | Q41167965 |
| | A murine model of experimental metastasis to bone and bone marrow. | Q41260616 |
| | Development of skeletal metastasis by human prostate cancer in athymic nude mice | Q41437580 |
| | Validity and usefulness of human tumor models established by intratibial cell inoculation in nude rats. | Q41476749 |
| | Histopathological assessment of prostate cancer bone osteoblastic metastases | Q41477497 |
| | Differentiation of muscle, fat, cartilage, and bone from progenitor cells present in a bone-derived clonal cell population: effect of dexamethasone | Q41552587 |
| | Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. | Q41644427 |
| | Secreted phosphoprotein mRNA is induced during multi-stage carcinogenesis in mouse skin and correlates with the metastatic potential of murine fibroblasts | Q41727981 |
| | Inhibition of hydroxyapatite formation by osteopontin phosphopeptides | Q41952663 |
| | Promotion of prostatic metastatic migration towards human bone marrow stoma by Omega 6 and its inhibition by Omega 3 PUFAs | Q41969297 |
| | Vascular endothelial growth factor A, secreted in response to transforming growth factor-β1 under hypoxic conditions, induces autocrine effects on migration of prostate cancer cells | Q42140629 |
| | Annexin II expressed by osteoblasts and endothelial cells regulates stem cell adhesion, homing, and engraftment following transplantation | Q42219222 |
| | Differential expression of osteonectin/SPARC during human prostate cancer progression | Q42485853 |
| | Isolation and characterization of PC-3 human prostatic tumor sublines which preferentially metastasize to select organs in S.C.I.D. mice | Q42808290 |
| | Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice | Q42819394 |
| | Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial | Q43250043 |
| | Osteopontin modulates prostate carcinoma invasive capacity through RGD-dependent upregulation of plasminogen activators | Q43944122 |
| | Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid. | Q44361901 |
| | Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer | Q44918129 |
| | Role of fibrillar structure of collagenous carrier in bone sialoprotein-mediated matrix mineralization and osteoblast differentiation | Q46280931 |
| | Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy | Q46393465 |
| | Biochemical markers for monitoring response to therapy: evidence for higher bone specificity by a novel marker compared with routine markers | Q46593222 |
| | Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases | Q46802463 |
| | Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of Wnt signalling | Q47620825 |
| | Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. | Q47705480 |
| | Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer | Q47842199 |
| | Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. | Q51803777 |
| | Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone. | Q52174533 |
| | Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. | Q52544804 |
| | Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. | Q52832843 |
| | A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. | Q53370776 |
| | Conditioned medium of fetal mouse long bone rudiments stimulates the formation of osteoclast precursor-like cells from mouse bone marrow. | Q54363573 |
| | Evaluation of metastatic potential in prostate carcinoma: an in vivo model | Q57000969 |
| | Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone | Q57570810 |
| | TGF-β signalling-related markers in cancer patients with bone metastasis | Q58614844 |
| | Direct evidence of lipid translocation between adipocytes and prostate cancer cells with imaging FTIR microspectroscopy | Q61639552 |
| | Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer | Q71667802 |
| | Osteoblast function and osteomalacia in metastatic prostate cancer | Q72930512 |
| | Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation | Q30441987 |
| | Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines | Q30472489 |
| | Prostate cancer derived prostatic acid phosphatase promotes an osteoblastic response in the bone microenvironment | Q30573685 |
| | Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases | Q30596578 |
| | A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. | Q30984959 |
| | Characterization of SV-40 Tag rats as a model to study prostate cancer | Q33403060 |
| | Transforming growth factor-beta1 attenuates expression of both the progesterone receptor and Dickkopf in differentiated human endometrial stromal cells | Q33643238 |
| | Pain management in patients with advanced prostate cancer | Q33784495 |
| | Mitf induction by RANKL is critical for osteoclastogenesis | Q33848784 |
| | Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database | Q33978299 |
| | Osteomimicry: how tumor cells try to deceive the bone | Q34022631 |
| | Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in prostate cancer bone metastasis | Q34147824 |
| | Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer | Q34340156 |
| | In silico discovery of androgen receptor antagonists with activity in castration resistant prostate cancer | Q34424735 |
| | Augmented osteolysis in SPARC-deficient mice with bone-residing prostate cancer | Q34497987 |
| | Clinical features of metastatic bone disease and risk of skeletal morbidity | Q34576366 |
| | Molecular pathway for cancer metastasis to bone | Q34600581 |
| | Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer | Q34655823 |
| | Metastasis suppression in prostate cancer | Q34708726 |
| | Arachidonic acid modulates the crosstalk between prostate carcinoma and bone stromal cells | Q34756844 |
| | Role of the endothelin axis and its antagonists in the treatment of cancer | Q34919570 |
| | Blockade of transforming growth factor-beta (TGFβ) signaling inhibits osteoblastic tumorigenesis by a novel human prostate cancer cell line | Q35024363 |
| | New Insights Into the Molecular Mechanisms of Action of Bisphosphonates | Q35552250 |
| | Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis | Q35679829 |
| | Bone and fat: old questions, new insights | Q35774928 |
| | Clinical development of anti-RANKL therapy | Q35901092 |
| | A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases | Q35978728 |
| | Enhancement of osteoclastic bone resorption and suppression of osteoblastic bone formation in response to reduced mechanical stress do not occur in the absence of osteopontin | Q36376203 |
| | Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption | Q36417911 |
| | Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer | Q36553506 |
| | Molecular mechanisms of action of bisphosphonates: current status. | Q36633778 |
| | TGF-β effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K/AKT/mTOR pathway | Q36771000 |
| | Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis | Q36831102 |
| | Down-regulation of BRCA2 expression by collagen type I promotes prostate cancer cell proliferation | Q40439945 |
| | Interaction between LRP5 and Frat1 mediates the activation of the Wnt canonical pathway. | Q40460835 |
| | JAGGED1 expression is associated with prostate cancer metastasis and recurrence | Q40508036 |
| | Osteopontin enhances the cell proliferation induced by the epidermal growth factor in human prostate cancer cells | Q40573946 |
| | Prostate cancer cell growth is modulated by adipocyte‐cancer cell interaction | Q40654839 |
| | Endothelin-1 is a potent regulator of human bone cell metabolism in vitro | Q73166864 |
| | Pathobiology of autochthonous prostate cancer in a pre‐clinical transgenic mouse model | Q73264118 |
| | Osteopontin expression by osteoclast and osteoblast progenitors in the murine bone marrow: demonstration of its requirement for osteoclastogenesis and its increase after ovariectomy | Q73456808 |
| | Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers | Q73770287 |
| | Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells | Q78052193 |
| | Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44V interaction enhances survival in gastrointestinal cancer cells | Q79856285 |
| | EGF-like ligands stimulate osteoclastogenesis by regulating expression of osteoclast regulatory factors by osteoblasts: implications for osteolytic bone metastases | Q80629050 |
| | Pathologic fractures correlate with reduced survival in patients with malignant bone disease | Q80974012 |
| | Patterns of metastasis by the human prostate cancer cell line PC-3 in athymic nude mice | Q93522450 |
| | Cancer to bone: a fatal attraction | Q36884628 |
| | Targeting uPA/uPAR in prostate cancer | Q36893941 |
| | The use of molecular markers of bone turnover in the management of patients with metastatic bone disease | Q36990793 |
| | Mesenchymal CD44 expression contributes to the acquisition of an activated fibroblast phenotype via TWIST activation in the tumor microenvironment | Q37156520 |
| | Bone marrow-derived cathepsin K cleaves SPARC in bone metastasis | Q37316559 |
| | Targeting ERBB receptors to inhibit metastasis: old hopes and new certainties | Q37387689 |
| | Loss of inhibition over master pathways of bone mass regulation results in osteosclerotic bone metastases in prostate cancer | Q37471582 |
| | Loss of TGF-β responsiveness in prostate stromal cells alters chemokine levels and facilitates the development of mixed osteoblastic/osteolytic bone lesions | Q37508329 |
| | WNT/Frizzled signalling: receptor-ligand selectivity with focus on FZD-G protein signalling and its physiological relevance: IUPHAR Review 3 | Q37635264 |
| | Tumor-stroma co-evolution in prostate cancer progression and metastasis | Q37641468 |
| | Pathogenesis of osteoblastic bone metastases from prostate cancer | Q37682761 |
| | Wnt and the Wnt signaling pathway in bone development and disease | Q37724188 |
| | Bone-marker levels in patients with prostate cancer: potential correlations with outcomes | Q37758181 |
| | Bone cells and the mechanisms of bone remodelling | Q37971731 |
| | The contribution of bone to whole-organism physiology | Q37977006 |
| | Bisphosphonates: prevention of bone metastases in prostate cancer | Q37981583 |
| | An overview of the regulation of bone remodelling at the cellular level. | Q37998757 |
| | Human osteopontin splicing isoforms: known roles, potential clinical applications and activated signaling pathways | Q38067985 |
| | Wnt signaling in stem and cancer stem cells | Q38076537 |
| | Endothelin 1 in cancer: biological implications and therapeutic opportunities | Q38123973 |
| | Secreted frizzled related proteins: Implications in cancers | Q38169447 |
| | Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption | Q38275140 |
| | Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer | Q38361625 |
| | Role of WNT7B-induced noncanonical pathway in advanced prostate cancer | Q39198747 |
| | Gefitinib inhibits the cross-talk between mesenchymal stem cells and prostate cancer cells leading to tumor cell proliferation and inhibition of docetaxel activity. | Q39236369 |
| | Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. | Q39279366 |
| | Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis | Q39305976 |
| | Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis | Q39365959 |
| | Bone-metastatic prostate carcinoma favors mesenchymal stem cell differentiation toward osteoblasts and reduces their osteoclastogenic potential. | Q39456241 |
| | Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer | Q39534721 |
| | Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells | Q39552934 |
| | Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites | Q39653979 |
| | Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice | Q40294747 |
| | Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism | Q40372846 |
| | Prostate cancer cells promote osteoblastic bone metastases through Wnts | Q40377933 |
| | BSP and RANKL induce osteoclastogenesis and bone resorption synergistically | Q40390865 |
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| | bone neoplasm | Q1328805 |
| | prostate neoplasm | Q56014511 |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 167035 | |
| P577 | publication date | 2014-05-28 | |
| P1433 | published in | BioMed Research International | Q17509958 |
| P1476 | title | Prostate cancer and bone: the elective affinities | |
| P478 | volume | 2014 | |